Intrinsiqq
⚠ Showing the latest available close (Jun 18, 2025, 491 days ago). Our price provider hasn't published a newer EOD for this ticker yet. Price-dependent metrics (P/E, P/FCF, yield) may not reflect current market conditions.
Aspira Women's Health Inc. logoAspira Women's Health Inc.AWHL
$0.1638+35.41%
Aspira Women's Health Inc. logo

Aspira Women's Health Inc.

AWHL

$0.16

+$0.04 (+35.41%)

⊜ Compare
ProfitabilityUnprofitableGrowthAcceleratingCash FlowCash burnValuationN/A
What stands out

The business is unprofitable at the operating level (-2307.00% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.

What's changing

Revenue up 8475.0% YoY with margins expanding 404643.0pp.

What deserves caution

Negative free cash flow of -$7M. The business is consuming cash, not generating it.

Price History

-90.0%

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$8M
EPS-$0.31
P/E-0.53
P/FCF-1.67
EV/EBITDA-1.49
FCF Yield—
Div. Yield—
Net Debt/FCF-0.6x

Profitability & Returns

Revenue (TTM)

$223K

▲ +8475.0% YoY

Net Income (TTM)

-$10M

▲ +2.4% YoY

Op. Margin

-3094.62%

▲ +404643.0pp YoY

ROIC

-167.55%

▲ +211.6pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$5M

▲ +42.0% YoY

Op. Cash Flow (TTM)

-$5M

▲ +42.0% YoY

Net Debt

$3M

Cash & Equiv.

$477K

5Y CAGR: -40.6%

Continue Research

SourceComputed from the 10-Q filed 12 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.

Price from market data, last close as of 18 Jun 2025. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.

Is Aspira Women's Health (AWHL) overvalued?

Aspira Women's Health (AWHL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.

On quality, Aspira Women's Health scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.

Frequently asked

Is Aspira Women's Health a high-quality business?+

Aspira Women's Health scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -3,094.6% operating margin and a -167.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.

Is Aspira Women's Health a good stock to buy right now?+

That depends on valuation and quality together, not either alone. you should weigh AWHL's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.

Related stocks: In Vitro & In Vivo Diagnostic Substances

Spot a number that looks wrong? Check it in AWHL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing AWHL

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.